Home > Therapy areas > Rheumatoid arthritis

PHASE II International have over a decade of rheumatoid arthritis
experience as indicated below:

1996 Pfizer's Cytokine modulator tenidap sodium (CP66, 248) - pre-launch development     1997 Early positioning work on Roche's Rheumatoid Arthritis portfolio (Cellcept® (mycofenolate mofetil, MMF); Lenercept (TNF); CPA (cartilage protection agent)     1998 Pre-launch work for Aventis ARAVA® (leflunomide)   2000/2001 ANAKINRA™ (kineret) for Rheumatoid Arthritis - New Technology Appraisal proposal   2002/2003 Onercept

For more information about PHASE II and our rheumatoid arthritis experience, please click here to contact us.